The efficacy and safety of lenvatinib plus pembrolizumab in vulnerable patients with metastatic or recurrent endometrial cancer: a single institution experience.
Yunokawa M, Abe A, Wang X, Toyohara Y, Nimura R, Komoto T, Misaka S, Yoshimitsu T, Ikki A, Kamata M, Nishino S, Kanno M, Fusegi A, Netsu S, Aoki Y, Omi M, Tanigawa T, Okamoto S, Nomura H, Kanao H.
Yunokawa M, et al. Among authors: nomura h.
Int J Clin Oncol. 2025 Feb;30(2):371-379. doi: 10.1007/s10147-024-02667-0. Epub 2024 Dec 6.
Int J Clin Oncol. 2025.
PMID: 39641902